| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = -$112 ) |
| | 2025 | 2023 | IMMUNEXT PHARMACEUTICALS | 1 MEDICAL CENTER DR | LEBANON | NH | 03756-1000 | GRAFTON | USA | R44AI165119 | Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases | 000 | 3 | NIH | 1/21/2025 | -$112 |
|
| Issue Date FY: 2024 ( Subtotal = -$993,646 ) |
| | 2024 | 2023 | IMMUNEXT PHARMACEUTICALS | 1 MEDICAL CENTER DR | LEBANON | NH | 03756-1000 | GRAFTON | USA | R44AI165119 | Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases | 000 | 3 | NIH | 6/25/2024 | -$993,646 |
|
| Issue Date FY: 2023 ( Subtotal = $993,758 ) |
| | 2023 | 2023 | IMMUNEXT, INC. | 1 MEDICAL CENTER DR | LEBANON | NH | 03756-1000 | GRAFTON | USA | R44AI165119 | Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases | 000 | 3 | NIH | 6/14/2023 | $993,758 |
| | 2023 | 2020 | IMMUNEXT, INC. | 1 MEDICAL CENTER DR | LEBANON | NH | 03756-1000 | GRAFTON | USA | R44AI138725 | Targeting leukocyte metabolism to treat human autoimmune disease | 000 | 4 | NIH | 9/12/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $974,853 ) |
| | 2022 | 2022 | IMMUNEXT, INC. | 1 MEDICAL CENTER DR | LEBANON | NH | 03756-1000 | GRAFTON | USA | R44AI165119 | Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases | 000 | 2 | NIH | 5/20/2022 | $974,853 |
|
| Issue Date FY: 2021 ( Subtotal = $990,946 ) |
| | 2021 | 2021 | IMMUNEXT, INC. | 1 MEDICAL CENTER DR | LEBANON | NH | 03756-1000 | GRAFTON | USA | R44AI165119 | Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases | 000 | 1 | NIH | 6/21/2021 | $990,946 |
| | 2021 | 2019 | IMMUNEXT, INC. | 1 MEDICAL CENTER DR | LEBANON | NH | 03756-1000 | GRAFTON | USA | R44AI129182 | Targeting the checkpoint regulator VISTA for treatment of inflammatory disease | 000 | 4 | NIH | 3/11/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $995,802 ) |
| | 2020 | 2020 | IMMUNEXT, INC. | 1 MEDICAL CENTER DR | LEBANON | NH | 03756-1000 | GRAFTON | USA | R44AI138725 | Targeting leukocyte metabolism to treat human autoimmune disease | 000 | 4 | NIH | 7/31/2020 | $995,802 |
|
| Issue Date FY: 2019 ( Subtotal = $1,883,209 ) |
| | 2019 | 2019 | IMMUNEXT, INC. | 1 MEDICAL CENTER DR | LEBANON | NH | 03756-1000 | GRAFTON | USA | R44AI138725 | Targeting leukocyte metabolism to treat human autoimmune disease | 000 | 3 | NIH | 6/26/2019 | $996,128 |
| | 2019 | 2019 | IMMUNEXT, INC. | 1 MEDICAL CENTER DR | LEBANON | NH | 03756-1000 | GRAFTON | USA | R44AI129182 | Targeting the checkpoint regulator VISTA for treatment of inflammatory disease | 000 | 4 | NIH | 7/16/2019 | $1,004,563 |
| | 2019 | 2017 | IMMUNEXT, INC. | 1 MEDICAL CENTER DR | LEBANON | NH | 03756-1000 | GRAFTON | USA | R44AI098261 | Safe and effective anti CD154 antibodies for therapeutic intervention | 000 | 6 | NIH | 8/27/2019 | -$117,482 |
|
| Issue Date FY: 2018 ( Subtotal = $2,287,344 ) |
| | 2018 | 2018 | IMMUNEXT, INC. | 1 MEDICAL CENTER DR | LEBANON | NH | 03756-1000 | GRAFTON | USA | R44AI138725 | Targeting leukocyte metabolism to treat human autoimmune disease | 001 | 2 | NIH | 8/14/2018 | $995,802 |
| | 2018 | 2018 | IMMUNEXT, INC. | 1 MEDICAL CENTER DR | LEBANON | NH | 03756-1000 | GRAFTON | USA | R44AI129182 | Targeting the checkpoint regulator VISTA for treatment of inflammatory disease | 000 | 3 | NIH | 7/30/2018 | $992,040 |
| | 2018 | 2018 | IMMUNEXT, INC. | 1 MEDICAL CENTER DR | LEBANON | NH | 03756-1000 | GRAFTON | USA | R44AI138725 | Targeting leukocyte metabolism to treat human autoimmune disease | 000 | 1 | NIH | 2/12/2018 | $299,502 |
| | 2018 | 2017 | IMMUNEXT, INC. | 1 MEDICAL CENTER DR | LEBANON | NH | 03756-1000 | GRAFTON | USA | R44AI129182 | Targeting the checkpoint regulator VISTA for treatment of inflammatory disease | 001 | 1 | NIH | 8/14/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $2,197,747 ) |
| | 2017 | 2017 | IMMUNEXT, INC. | 1 MEDICAL CENTER DR | LEBANON | NH | 03756-1000 | GRAFTON | USA | R44AI129182 | Targeting the checkpoint regulator VISTA for treatment of inflammatory disease | 000 | 1 | NIH | 2/10/2017 | $299,938 |
| | 2017 | 2017 | IMMUNEXT, INC. | 1 MEDICAL CENTER DR | LEBANON | NH | 03756-1000 | GRAFTON | USA | R44AI129182 | Targeting the checkpoint regulator VISTA for treatment of inflammatory disease | 001 | 2 | NIH | 8/7/2017 | $991,804 |
| | 2017 | 2017 | IMMUNEXT, INC. | 1 MEDICAL CENTER DR | LEBANON | NH | 03756-1000 | GRAFTON | USA | R44AI098261 | Safe and effective anti CD154 antibodies for therapeutic intervention | 001 | 6 | NIH | 4/27/2017 | $912,191 |
| | 2017 | 2015 | IMMUNEXT, INC. | 1 MEDICAL CENTER DR | LEBANON | NH | 03756-1000 | GRAFTON | USA | R42AI100418 | Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease | 000 | 4 | NIH | 8/17/2017 | -$6,186 |
| | 2017 | 2015 | IMMUNEXT, INC. | 1 MEDICAL CENTER DR | LEBANON | NH | 03756-1000 | GRAFTON | USA | R44AI098261 | Safe and effective anti CD154 antibodies for therapeutic intervention | 000 | 4 | NIH | 4/18/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $912,191 ) |
| | 2016 | 2016 | IMMUNEXT INC | 16 CAVENDISH COURT | LEBANON | NH | 03766 | GRAFTON | USA | R44AI098261 | Safe and effective anti CD154 antibodies for therapeutic intervention | 000 | 5 | NIH | 5/9/2016 | $912,191 |
|
| Issue Date FY: 2015 ( Subtotal = $1,954,097 ) |
| | 2015 | 2015 | IMMUNEXT INC | 16 CAVENDISH COURT | LEBANON | NH | 03766 | GRAFTON | USA | R44AI098261 | Safe and effective anti CD154 antibodies for therapeutic intervention | 000 | 4 | NIH | 2/27/2015 | $1,000,000 |
| | 2015 | 2015 | IMMUNEXT INC | 16 CAVENDISH COURT | LEBANON | NH | 03766 | GRAFTON | USA | R42AI100418 | Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease | 000 | 4 | NIH | 4/3/2015 | $954,097 |
|
| Issue Date FY: 2014 ( Subtotal = $1,957,856 ) |
| | 2014 | 2014 | IMMUNEXT INC | 16 CAVENDISH COURT | LEBANON | NH | 03766 | GRAFTON | USA | R44AI098261 | Safe and effective anti CD154 antibodies for therapeutic intervention | 000 | 3 | NIH | 2/28/2014 | $962,696 |
| | 2014 | 2014 | IMMUNEXT INC | 16 CAVENDISH COURT | LEBANON | NH | 03766 | GRAFTON | USA | R42AI100418 | Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease | 000 | 3 | NIH | 2/14/2014 | $995,160 |
|
| Issue Date FY: 2013 ( Subtotal = $1,588,916 ) |
| | 2013 | 2013 | IMMUNEXT INC | 16 CAVENDISH COURT | LEBANON | NH | 03766 | GRAFTON | USA | R44AI098261 | Safe and effective anti CD154 antibodies for therapeutic intervention | 000 | 2 | NIH | 1/30/2013 | $998,002 |
| | 2013 | 2013 | IMMUNEXT INC | 16 CAVENDISH COURT | LEBANON | NH | 03766 | GRAFTON | USA | R41AI100418 | VALIDATION OF A NEGATIVE REGULATOR AS A NOVEL THERAPY FOR AUTOIMMUNE DISEASE | 000 | 2 | NIH | 4/8/2013 | $300,000 |
| | 2013 | 2013 | IMMUNEXT INC | 16 CAVENDISH COURT | LEBANON | NH | 03766 | GRAFTON | USA | R41AI102375 | SAFE AND EFFECTIVE ANTI-CD154 ANTIBODIES FOR THERAPEUTIC INTERVENTION | 000 | 1 | NIH | 12/12/2012 | $290,914 |
|
| Issue Date FY: 2012 ( Subtotal = $600,000 ) |
| | 2012 | 2012 | IMMUNEXT INC | 16 CAVENDISH COURT | LEBANON | NH | 03766 | GRAFTON | USA | R43AI096682 | VISTA: A NOVEL THERAPEUTIC TARGET THAT NEGATIVELY REGULATES IMMUNITY | 000 | 2 | NIH | 8/16/2012 | $300,000 |
| | 2012 | 2012 | IMMUNEXT INC | 16 CAVENDISH COURT | LEBANON | NH | 03766 | GRAFTON | USA | R41AI100418 | VALIDATION OF A NEGATIVE REGULATOR AS A NOVEL THERAPY FOR AUTOIMMUNE DISEASE | 000 | 1 | NIH | 4/20/2012 | $300,000 |
|
|
